The key role of genomics in modern vaccine and drug design for emerging infectious diseases

PLoS Genetics

Volumn 5, Issue 10, 2009, Pages

  Seib, Kate L ^a   Dougan, Gordon ^b   Rappuoli, Rino ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; COMPLEMENTARY DNA; DNA; EPITOPE; GENE PRODUCT; OUTER SURFACE PROTEIN A; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOINFORMATICS; COMPARATIVE GENE MAPPING; CORONAVIRUS; CRYSTALLOGRAPHY; DENGUE; DIARRHEA; DNA MICROARRAY; DNA POLYMORPHISM; DRUG DESIGN; DRUG TARGETING; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; HELICOBACTER PYLORI; HEMOLYTIC UREMIC SYNDROME; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION; INFLUENZA VIRUS A H1N1; MENINGITIS; METABOLOMICS; METAGENOMICS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUMPS VIRUS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OPEN READING FRAME; PATHOGENESIS; PHARMACOGENETICS; PNEUMONIA; PREVENTION AND CONTROL; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA TRANSCRIPTION; SEPTICEMIA; SEVERE ACUTE RESPIRATORY SYNDROME; STOMACH CANCER; STOMACH ULCER; STREPTOCOCCUS PYOGENES; STRUCTURAL GENOMICS; T LYMPHOCYTE; TRANSCRIPTOMICS; URINARY TRACT INFECTION; VACCINATION; VIRULENCE; COMMUNICABLE DISEASE; GENETICS; GENOME; IMMUNIZATION;

COMMUNICABLE DISEASES; DNA; DRUG DESIGN; GENOME; GENOMICS; HUMANS; IMMUNIZATION; VACCINES;

EID: 70350479576     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1000612     Document Type: Review

References (87)

1. Dong J, Olano JP, McBride JW, Walker DH (2008) Emerging pathogens: Challenges and successes of molecular diagnostics. J Mol Diagn 10: 185-197.
2. Yang X, Yang H, Zhou G, Zhao GP (2008) Infectious disease in the genomic era. Annu Rev Genomics Hum Genet 9: 21-48.
3. Rappuoli R (2007) Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25: 1361-1366.
4. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, et al. (1995) Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269: 496-512.
5. Casanova JL, Abel L (2007) Human genetics of infectious diseases: A unified theory. EMBO J 26: 915-922.
6. Burgner D, Jamieson SE, Blackwell JM (2006) Genetic susceptibility to infectious diseases: Big is beautiful, but will bigger be even better? Lancet Infect Dis 6:653-663.
7. Nakamura S, Yang CS, Sakon N, Ueda M, Tougan T, et al. (2009) Direct metagenomic detection of viral pathogens in nasal and fecal specimens using an unbiased high-throughput sequencing approach. PLoS ONE 4: e4219. doi:10.1371/journal.pone.0004219.
8. Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, et al. (2008) Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 3: e2908. doi:10.1371/journal.pone.0002908.
9. Rinaudo CD, Telford JL, Rappuoli R, Seib KL (2009) Vaccinology in the genome era. J Clin Invest 119: 2515-2525.
10. Kaushik DK, Sehgal D (2008) Developing antibacterial vaccines in genomics and proteomics era. Scand J Immunol 67: 544-552.
11. Pucci MJ (2007) Novel genetic techniques and approaches in the microbial genomics era: identification and/or validation of targets for the discovery of new antibacterial agents. Drugs R D 8: 201-212.
12. Mills SD (2006) When will the genomics investment pay off for antibacterial discovery? Biochem Pharmacol 71: 1096-1102.
13. Van Voorhis WC, Hol WGJ, Myler PJ, Stewart LJ (2009) The role of medical structural genomics in discovering new drugs for infectious diseases. PLoS Comput Biol 5(10): e530. 10.1371/journal.pcbi.1000530.
14. Masignani V, Rappuoli R, Pizza M (2002) Reverse vaccinology: A genome-based approach for vaccine development. Expert Opin Biol Ther 2: 895-905.
15. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816-1820.
16. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103: 10834-10839.
17. Rappuoli R (2008) The application of reverse vaccinology, Novartis MenB vaccine developed by design. 16th International Pathogenic Neisseria Conference, Rotterdam, The Netherlands: http://www.IPNC2008.org. Abstr. 81 p.
18. Muzzi A, Masignani V, Rappuoli R (2007) The pan-genome: Towards a knowledge-based discovery of novel targets for vaccines and antibacterials. Drug Discov Today 12: 429-439.
19. Tettelin H,Masignani V, CieslewiczMJ, Donati C, Medini D, et al. (2005)Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome." Proc Natl Acad Sci U S A 102: 13950-13955.
20. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, et al. (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309: 148-150.
21. Bhagwat AA, Bhagwat M (2008) Methods and tools for comparative genomics of foodborne pathogens. Foodborne Pathog Dis 5: 487-497.
22. Rasko DA, Rosovitz MJ, Myers GS, Mongodin EF, Fricke WF, et al. (2008) The pangenome structure of Escherichia coli: Comparative genomic analysis of E. coli commensal and pathogenic isolates. J Bacteriol 190: 6881-6893.
23. Holt KE, Parkhill J, Mazzoni CJ, Roumagnac P, Weill FX, et al. (2008) Highth-roughput sequencing provides insights into genome variation and evolution in Salmonella typhi. Nat Genet 40: 987-993.
24. Dhiman N, Bonilla R, O'Kane DJ, Poland GA (2001) Gene expression microarrays: A 21st century tool for directed vaccine design. Vaccine 20: 22-30.
25. Morozova O, Marra MA (2008) Applications of next-generation sequencing technologies in functional genomics. Genomics 92: 255-264.
26. Merrell DS, Butler SM, Qadri F, Dolganov NA, Alam A, et al. (2002) Host-induced epidemic spread of the cholera bacterium. Nature 417: 642-645.
27. Talaat AM, Lyons R, Howard ST, Johnston SA (2004) The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci U S A 101: 4602-4607.
28. Scarselli M, Giuliani MM, Adu-Bobie J, Pizza M, Rappuoli R (2005) The impact of genomics on vaccine design. Trends Biotechnol 23: 84-91.
29. Saenz HL, Dehio C (2005) Signature-tagged mutagenesis: technical advances in a negative selection method for virulence gene identification. Curr Opin Microbiol 8: 612-619.
30. Sakata T, Winzeler EA (2007) Genomics, systems biology and drug development for infectious diseases. Mol Biosyst 3: 841-848.
31. Sun YH, Bakshi S, Chalmers R, Tang CM (2000) Functional genomics of Neisseria meningitidis pathogenesis. Nat Med 6: 1269-1273.
32. Kavermann H, Burns BP, Angermuller K, Odenbreit S, Fischer W, et al. (2003) Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J Exp Med 197: 813-822.
33. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
34. Zhu H, Bilgin M, Snyder M (2003) Proteomics. Annu Rev Biochem 72:783-812.
35. Grandi G (2006) Genomics and proteomics in reverse vaccines. Methods Biochem Anal 49: 379-393.
36. Rodriguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, et al. (2006) Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 24:191-197.
37. De Groot AS, McMurry J, Moise L (2008) Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:620-626.
38. Meinke A, Henics T, Hanner M, Minh DB, Nagy E (2005) Antigenome technology: A novel approach for the selection of bacterial vaccine candidate antigens. Vaccine 23: 2035-2041.
39. Vytvytska O, Nagy E, Bluggel M, Meyer HE, Kurzbauer R, et al. (2002) Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2: 580-590.
40. Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, et al. (2008) Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 205:117-131.
41. Eyles JE, Unal B, Hartley MG, Newstead SL, Flick-Smith H, et al. (2007) Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics 7: 2172-2183.
42. Rolfs A, Montor WR, Yoon SS, Hu Y, Bhullar B, et al. (2008) Production and sequence validation of a complete full length ORF collection for the pathogenic bacterium Vibrio cholerae. Proc Natl Acad Sci U S A 105: 4364-4369.
43. Stoevesandt O, Taussig MJ, He M (2009) Protein microarrays: high-throughput tools for proteomics. Expert Rev Proteomics 6: 145-157.
44. De Groot AS, Moise L, McMurry JA, Martin W (2008) Epitope-based immunone-derived vaccines: a strategy for improved design and safety. In: Falus A, ed. Clinical Applications of Immunomics. New York: Springer. pp 39-69.
45. Sette A, Fleri W, Peters B, Sathiamurthy M, Bui HH, et al. (2005) A roadmap for the immunomics of category A-C pathogens. Immunity 22: 155-161.
46. De Groot AS, Rivera DS, McMurry JA, Buus S, Martin W (2008) Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. Vaccine 26: 3059-3071.
47. Lundstrom K (2007) Structural genomics and drug discovery. J Cell Mol Med 11: 224-238.
48. Kaldor SW, Kalish VJ, Davies JF, 2nd, Shetty BV, Fritz JE, et al. (1997) Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 40: 3979-3985.
49. Kim CU, Lew W, Williams MA, Liu H, Zhang L, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-690.
50. Todd AE, Marsden RL, Thornton JM, Orengo CA (2005) Progress of structural genomics initiatives: An analysis of solved target structures. J Mol Biol 348:1235-1260.
51. Dormitzer PR, Ulmer JB, Rappuoli R (2008) Structure-based antigen design: A strategy for next generation vaccines. Trends Biotechnol 26: 659-667.
52. Nicola G, Abagyan R (2009) Structure-based approaches to antibiotic drug discovery. Curr Protoc Microbiol Chapter 17: Unit 17.2.
53. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
54. Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS, KuanTeh J (2007) Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. In: Advances in Pharmacology. Academic Press. pp 33-97.
55. Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, et al. (2008) Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26:6189-6199.
56. Ercolini AM, Miller SD (2009) The role of infections in autoimmune disease. Clin Exp Immunol 155: 1-15.
57. Amela I, Cedano J, Querol E (2007) Pathogen proteins eliciting antibodies do not share epitopes with host proteins: A bioinformatics approach. PLoS ONE 2:e512. doi:10.1371/journal.pone.0000512.
58. Kanduc D, Stufano A, Lucchese G, Kusalik A (2008) Massive peptide sharing between viral and human proteomes. Peptides 29: 1755-1766.
59. Kanduc D, Lucchese A, Mittelman A (2007) Non-redundant peptidomes from DAPs: Towards "the vaccine"? Autoimmun Rev 6: 290-294.
60. Wraith DC, Goldman M, Lambert PH (2003) Vaccination and autoimmune disease: What is the evidence? Lancet 362: 1659-1666.
61. Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, et al. (1998) Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281: 703-706.
62. Willett TA, Meyer AL, Brown EL, Huber BT (2004) An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc Natl Acad Sci U S A 101: 1303-1308.
63. Kellam P (2006) Attacking pathogens through their hosts. Genome Biol 7: 201.
64. Andeweg AC, Haagmans BL, Osterhaus AD (2008) Virogenomics: the virus-host interaction revisited. Curr Opin Microbiol 11: 461-466.
65. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, et al. (2004) Statins inhibit HIV-1 infection by down-regulating Rho activity. J ExpMed 200: 541-547.
66. de Lang A, Baas T, Teal T, Leijten LM, Rain B, et al. (2007) Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. PLoS Pathog 3: e112. doi:10.1371/journal. ppat.0030112.
67. International HapMap Consortium (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861.
68. Poland GA, Ovsyannikova IG, Jacobson RM (2009) Application of pharmacogenomics to vaccines. Pharmacogenomics 10: 837-852.
69. Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, et al. (2008) Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 121: e1091-1099.
70. Sim E, Lack N, Wang CJ, Long H, Westwood I, et al. (2008) Arylamine Nacetyltransferases: Structural and functional implications of polymorphisms. Toxicology 254: 170-183.
71. Baudhuin LM, Langman LJ, O'Kane DJ (2007) Translation of pharmacogenetics into clinically relevant testing modalities. Clin Pharmacol Ther 82:373-376.
72. Telford JL, Barocchi MA, Margarit I, Rappuoli R, Grandi G (2006) Pili in gram-positive pathogens. Nat Rev Microbiol 4: 509-519.
73. Lauer P, Rinaudo CD, Soriani M, Margarit I, Maione D, et al. (2005) Genome analysis reveals pili in Group B Streptococcus. Science 309: 105.
74. Margarit I, Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, et al. (2009) Preventing bacterial infections with pilus-based vaccines: The group B streptococcus paradigm. J Infect Dis 199: 108-115.
75. Mora M, Bensi G, Capo S, Falugi F, Zingaretti C, et al. (2005) Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci U S A 102: 15641-15646.
76. Falugi F, Zingaretti C, Pinto V, Mariani M, Amodeo L, et al. (2008) Sequence variation in Group A Streptococcus pili and association of pilus backbone types with Lancefield T serotypes. J Infect Dis 198: 1834-1841.
77. Barocchi MA, Ries J, Zogaj X, Hemsley C, Albiger B, et al. (2006) A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A 103: 2857-2862.
78. Bagnoli F, Moschioni M, Donati C, Dimitrovska V, Ferlenghi I, et al. (2008) A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol 190: 5480-5492.
79. Gianfaldoni C, Censini S, Hilleringmann M, Moschioni M, Facciotti C, et al. (2007) Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun 75: 1059-1062.
80. Granoff DM, Welsch JA, Ram S (2009) Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77: 764-769.
81. McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris S, et al. (2009) Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27: 3417-3421.
82. Koeberling O, Seubert A, Granoff DM (2008) Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198:262-270.
83. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177:501-510.
84. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, et al. (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197: 789-799.
85. Welsch JA, Ram S, Koeberling O, Granoff DM (2008) Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197:1053-1061.
86. Seib KL, Serruto D, Oriente F, Delany I, Adu-Bobie J, et al. (2009) Factor Hbinding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77: 292-299.
87. Mazurkiewicz P, Tang CM, Boone C, Holden DW (2006) Signature-tagged mutagenesis: Barcoding mutants for genome-wide screens. Nat Rev Genet 7:929-939.